Boston Scientific reports Q4 and full year 2025 results, announces acquisitions

BOSTON SCIENTIFIC CORP

2025-FY EPS reported $1.94 revenue$20,074,000,000

Q4 2025 net sales $5.286B, up 15.9% reported; GAAP EPS $0.45, adjusted EPS $0.80.
FY2025 net sales $20.074B, up 19.9%; GAAP net income $2.898B, adjusted EPS $3.06.
Agreed to acquire Penumbra (PEN), a thrombectomy and neurovascular company.
Agreed to acquire Valencia Technologies for its eCoin tibial nerve stimulation device.
Completed acquisition of Nalu Medical for peripheral nerve stimulation system.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.